Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Formoterol used as needed--clinical effectiveness.

O Selroos1

  • 1AstraZeneca R&D, Clinical Science, Lund, Sweden. olof.selroos@astraZeneca.com

Respiratory Medicine
|September 6, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease marker combination enhances patient characterization in the Finnish sarcoidosis patients.

Respiratory medicine·2017
Same author

Global Asthma Network survey suggests more national asthma strategies could reduce burden of asthma.

Allergologia et immunopathologia·2017
Same author

Clinical relevance is associated with allergen-specific wheal size in skin prick testing.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2013
Same author

Comparing asthma treatment in elderly versus younger patients.

Respiratory medicine·2011
Same author

True adherence with the Turbuhaler in young children with asthma.

Archives of disease in childhood·2010
Same author

Unaffected peak inspiratory flow through Turbuhaler during histamine inhalation challenge.

Allergy·2010

Formoterol, a fast- and long-acting beta2-agonist, shows effectiveness as a reliever medication for asthma. It improves lung function and reduces exacerbations, supporting its use for effective asthma control.

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Clinical Therapeutics

Background:

  • Formoterol is a long-acting beta2-agonist (LABA) established for maintenance therapy in asthma.
  • Its unique mechanism provides both rapid and sustained bronchodilation.
  • The potential for formoterol as a reliever medication warrants investigation.

Purpose of the Study:

  • To evaluate the efficacy of formoterol as a first-line reliever medication in asthma.
  • To compare formoterol's effectiveness against other relievers and its role in exercise-induced bronchoconstriction.

Main Methods:

  • Systematic review of studies assessing formoterol's use as needed for asthma.
  • Comparison of formoterol with terbutaline and salbutamol in mild-to-severe asthma.
  • Assessment of protection against exercise-induced bronchoconstriction.

Related Experiment Videos

Main Results:

  • Formoterol as needed demonstrated superior efficacy over terbutaline in mild-to-moderate asthma, improving peak flow and reducing exacerbations.
  • In moderate-to-severe asthma, formoterol showed comparable efficacy to salbutamol and terbutaline for symptom and lung function improvement.
  • Single and repeated doses of formoterol provided significant protection against exercise-induced bronchoconstriction for up to 12 hours.

Conclusions:

  • Formoterol is effective and well-tolerated as a reliever medication for acute asthma attacks.
  • Evidence supports the use of formoterol on an as-needed basis for comprehensive asthma control.
  • Further research is needed to confirm long-term protection with frequent formoterol use.